TenNor Therapeutics is a global clinical-stage company with a sharp focus on discovery and development of differentiated products to address unmet medical needs in infectious disease area. The company possesses a novel multi-targeting drug conjugate platform and a globally protected new drug development portfolio. Multiple products are currently in phase 2-3 clinical development, targeting medical device associated bacterial biofilm infections, cirrhosis encephalopathy and Helicobacter pylori infection.
TenNor is led by an experienced management team with successful track record in discovery and development of new drugs in infectious disease area. The company is supervised by a Board of Directors consisting of a group of experienced life science investors and a Scientific Advisory Board formed by a group of world leading scientists and clinicians, including members of the National Academy of Sciences, USA. TenNor adopts a highly efficient operating model, combining internal disease specific expertise with external CRO drug development platform to rapidly advance its new drug development portfolio. The company has raised more than $30 million US dollars through three rounds of financing.